| Literature DB >> 26666517 |
Julia Herzog1, Raphaela Rid2, Martin Wagner3, Harald Hundsberger4, Andreas Eger5, Johann Bauer6, Kamil Önder7.
Abstract
BACKGROUND: To be able to develop effective therapeutics for epidermolysis bullosa simplex (EBS), it is necessary to elucidate the molecular pathomechanisms that give rise to the disease's characteristic severe skin-blistering phenotype.Entities:
Mesh:
Year: 2015 PMID: 26666517 PMCID: PMC4678661 DOI: 10.1186/s13104-015-1783-7
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Fig. 1Experimental design of our study
Genes regulated in the EBS-DM model keratinocyte cell line KEB7 identified by microarray analysis
| Microarray candidate genes (accession number) | Regulation microarray | log2 fold-change microarray | Fold-change qRT-PCR | Significance of qRT-PCR (fold-change set −2) |
|---|---|---|---|---|
| KRT19 (NM_002276) | Significant down-regulated | −5.74 | −1633.0 | Significant |
| MIR492 (NR_030171) | Significant down-regulated | −4.46 | n.d. | n.d. |
| KYNU (NM_003937) | Significant down-regulated | −4.20 | −276.6 | Significant |
| H19, MIR675 (NR_030533) | Significant down-regulated | −4.12 | n.d. | n.d. |
| EYA4 (NM_004100) | Significant down-regulated | −4.03 | n.d. | n.d. |
| PDZK1 (NM_002614) | Significant down-regulated | −3.86 | −8.0 | Significant |
| TMPRSS15 (NM_002772) | Significant down-regulated | −3.85 | n.d. | n.d. |
| OLFM4 (NM_006418) | Significant down-regulated | −3.73 | −8.4 | Significant |
| SLC38A4 (NM_018018) | Significant down-regulated | −3.67 | −12.3 | Significant |
| BST2 (NM_004335) | Significant down-regulated | −3.53 | −137.3 | Significant |
| ITGBL1 (NM_004791) | Significant down-regulated | −2.99 | n.d. | n.d. |
| EDIL3 (NM_005711) | Significant down-regulated | −2.91 | n.d. | n.d. |
| PPARGC1A (NM_013261) | Significant down-regulated | −2.79 | −964.3 | Significant |
| GALNT5 (NM_014568) | Significant down-regulated | −2.73 | −78.3 | Significant |
| CDR1 (NM_004065) | Significant down-regulated | −2.71 | n.d. | n.d. |
| FKBP10 (NM_021939) | Significant down-regulated | −2.63 | −26.8 | Significant |
| GIPC2 (NM_017655) | Significant down-regulated | −2.55 | −71.4 | Significant |
| AMOT (NM_001113490) | Significant down-regulated | −2.53 | −3015.8 | Significant |
| ZNF114 (NM_153608) | Significant down-regulated | −2.52 | −10.2 | Significant |
| CLEC2B (NM_005127) | Significant down-regulated | −2.50 | −182.1 | Significant |
| FAM198B (NM_001031700) | Significant down-regulated | −2.50 | −14.0 | Significant |
| SLC2A3 (NM_006931) | Significant down-regulated | −2.48 | −88.7 | Significant |
| CAPNS2 (NM_032330) | Significant down-regulated | −2.43 | −9.0 | Significant |
| TBX18 (NM_001080508) | Significant down-regulated | −2.43 | −89.4 | Significant |
| LRCH2 (NM_020871) | Significant down-regulated | −2.36 | −44.2 | Significant |
| NEFM (NM_005382) | Significant down-regulated | −2.34 | −7.7 | Significant |
| CPT1C (NM_001136052) | Significant down-regulated | −2.32 | −13.4 | Significant |
| ZNF43 (NM_001256648) | Significant down-regulated | −2.22 | −9.7 | Significant |
| LY75, LY75-CD302 (NM_002349) | Significant down-regulated | −2.17 | −8.6 | Significant |
| LOC100129717, NEFL (NM_006158) | Significant down-regulated | −2.16 | n.d. | n.d. |
| GLDC (NM_000170) | Significant down-regulated | −2.14 | −307.6 | Significant |
| TMTC1 (NM_001193451) | Significant down-regulated | −2.13 | −6.7 | Significant |
| SLCO1B3 (NM_019844) | Significant down-regulated | −2.10 | −988.0 | Significant |
| SMOC2 (NM_022138) | Significant down-regulated | −2.09 | n.d. | n.d. |
| SLC6A14 (NM_007231) | Significant down-regulated | −2.02 | −4.9 | Significant |
| SLC24A3 (NM_020689) | Significant down-regulated | −1.97 | −53.0 | Significant |
| EPSTI1 (NM_001002264) | Significant down-regulated | −1.96 | −10.8 | Significant |
| SATB2 (NM_001172509) | Significant down-regulated | −1.94 | −224.2 | Significant |
| HSD17B2 (NM_002153) | Significant down-regulated | −1.89 | −59.8 | Significant |
| GHR (NM_000163) | Significant down-regulated | −1.87 | n.d. | n.d. |
| TFPI2 (NM_006528) | Significant down-regulated | −1.86 | n.d. | n.d. |
| AKR1B10 (NM_020299) | Significant down-regulated | −1.86 | −3.8 | Significant |
| ARHGAP28 (NM_001010000) | Significant down-regulated | −1.81 | n.d. | n.d. |
| LOC100506941, NNMT (NM_006169) | Significant down-regulated | −1.81 | n.d. | n.d. |
| GPC3 (NM_001164617) | Significant down-regulated | −1.81 | −427.1 | Significant |
| IFITM3 (JQ610621) | Significant down-regulated | −1.80 | −8.7 | Significant |
| HOXD10 (NM_002148) | Significant down-regulated | −1.79 | −100.8 | Significant |
| MSX2 (NM_002449) | Significant down-regulated | −1.77 | −9.5 | Significant |
| IL17RB (NM_018725) | Significant down-regulated | −1.75 | −9.1 | Significant |
| BLMH (NM_000386) | Significant down-regulated | −1.74 | −4.8 | Significant |
| SOX2 (NM_003106) | Significant down-regulated | −1.72 | n.d. | n.d. |
| HIST1H | Significant down-regulated | −1.70 | n.d. | n.d. |
| SLC9A2 (NM_003048) | Significant down-regulated | −1.69 | −17.0 | Significant |
| CPNE1, RBM12 (NM_006047) | Significant down-regulated | −1.68 | −14.9 | Significant |
| WDR17 (NM_170710) | Significant down-regulated | −1.60 | −11.2 | Significant |
| RB1 (NM_000321) | Significant down-regulated | −1.58 | −4.4 | Significant |
| DPYD (NM_000110) | Significant down-regulated | −1.57 | −3.7 | Significant |
| PCCA (NM_000282) | Significant down-regulated | −1.56 | n.d. | n.d. |
| ZNF570 (NM_001300993) | Significant down-regulated | −1.51 | n.d. | n.d. |
| PRTFDC1 (NM_020200) | Significant down-regulated | −1.49 | n.d. | n.d. |
| GLRX (NM_002064) | Significant down-regulated | −1.47 | −2.8 | Significant |
| SLC7A2 (NM_003046) | Significant down-regulated | −1.45 | −1.5 | Non-significant |
| PPP1R16B (NM_015568) | Significant down-regulated | −1.44 | −8.0 | Significant |
| IKZF3 (NM_012481) | Significant down-regulated | −1.41 | −1.8 | Non-significant |
| GTF2H2D | Significant down-regulated | −1.40 | −4.2 | Significant |
| CDK14 (NM_001287135) | Significant down-regulated | −1.40 | n.d. | n.d. |
| REPS2 (NM_004726) | Significant down-regulated | −1.38 | −4.5 | Significant |
| MEST (NM_002402) | Significant down-regulated | −1.38 | n.d. | n.d. |
| CYP4V2 (NM_207352) | Significant down-regulated | −1.35 | −4.7 | Significant |
| GPR143 (NM_000273) | Significant down-regulated | −1.35 | −2.1 | Significant |
| GTF2H2 (NM_001515) | Significant down-regulated | −1.35 | −4.0 | Significant |
| CYP7B1 (NM_004820) | Significant down-regulated | −1.32 | n.d. | n.d. |
| BCL11A (NM_022893) | Significant down-regulated | −1.31 | −3.6 | Significant |
| MERTK (NM_006343) | Significant down-regulated | −1.30 | −5.0 | Significant |
| PRDM5 (NM_018699) | Significant down-regulated | −1.28 | −6.1 | Significant |
| ACOXL (NM_001142807) | Significant down-regulated | −1.28 | −11.6 | Significant |
| AHCY (NM_000687) | Significant down-regulated | −1.27 | −2.0 | Significant |
| ARMCX2 (NM_177949) | Significant down-regulated | −1.24 | −22.5 | Significant |
| PAX6 (NM_000280) | Significant down-regulated | −1.23 | −14.2 | Significant |
| HOXD11 (NM_021192) | Significant down-regulated | −1.23 | −49.4 | Significant |
| SMARCA1 (NM_003069) | Significant down-regulated | −1.22 | −4.1 | Significant |
| IFI44L (NM_006820) | Significant down-regulated | −1.22 | −57.0 | Significant |
| GALNTL4 | Significant down-regulated | −1.20 | n.d. | n.d. |
| PITRM1 (NM_001242307) | Significant down-regulated | −1.19 | −2.3 | Significant |
| CRIP2 (NM_001312) | Significant down-regulated | −1.18 | n.d. | n.d. |
| NAP1L5 (NM_153757) | Significant down-regulated | −1.15 | −20.7 | Significant |
| IPO7 (NM_006391) | Significant down-regulated | −1.15 | n.d. | n.d. |
| SAAL1 (NM_138421) | Significant down-regulated | −1.13 | n.d. | n.d. |
| KRTCAP3 (NM_001168364) | Significant down-regulated | −1.12 | n.d. | n.d. |
| FAM159A (NM_001042693) | Significant down-regulated | −1.11 | n.d. | n.d. |
| EYA1 (NM_172060) | Significant down-regulated | −1.09 | n.d. | n.d. |
| PIGU (NM_080476) | Significant down-regulated | −1.09 | −3.2 | Significant |
| CDC25B (NM_021873) | Significant down-regulated | −1.09 | n.d. | n.d. |
| NKX2-6 (NM_001136271) | Significant down-regulated | −1.07 | n.d. | n.d. |
| HTATIP2 (NM_001098520) | Significant down-regulated | −1.05 | n.d. | n.d. |
| ILK (NM_004517) | Significant down-regulated | −1.05 | n.d. | n.d. |
| ACSF2 (NM_001288968) | Significant down-regulated | −1.04 | n.d. | n.d. |
| PDZD2 (NM_178140) | Significant down-regulated | −1.03 | n.d. | n.d. |
| CENPH (NM_022909) | Significant down-regulated | −1.03 | n.d. | n.d. |
| TOX (NM_014729) | Significant down-regulated | −1.02 | n.d. | n.d. |
| VSTM2L (NM_080607) | Significant down-regulated | −1.01 | n.d. | n.d. |
| SYT17 (NM_016524) | Significant down-regulated | −1.01 | n.d. | n.d. |
106 up-regulated and 101 down-regulated genes with significantly altered expression levels (log2-fold-change >+1 and <−1 and adjusted p-value <0.05) in the mutant cell line KEB7 compared to wild-type control NEB1 keratinocytes. qRT-PCR analysis of the most promising 79 up-regulated and 79 down-regulated genes was also carried out (a fold-change >±2 is statistically significant, p < 0.05)
Gene ontology (GO) functional annotation clustering
| Cluster | GO# | Term | Annotated | Significant | Expected | p value |
|---|---|---|---|---|---|---|
| (1)—16 clusters | ||||||
| 1 | GO:0050680 | Negative regulation of epithelial cell proliferation | 42 | 5 | 0.4881 | 0.0001 |
| 2 | GO:0001658 | Branching involved in ureteric bud morphogenesis | 41 | 4 | 0.4765 | 0.0013 |
| 3 | GO:0009954 | Proximal/distal pattern formation | 21 | 3 | 0.2440 | 0.0018 |
| 4 | GO:0034341 | Response to interferon-gamma | 19 | 3 | 0.2208 | 0.0013 |
| 5 | GO:0034613 | Cellular protein localization | 36 | 4 | 0.4183 | 0.0008 |
| 6 | GO:0090103 | Cochlea morphogenesis | 20 | 3 | 0.2324 | 0.0015 |
| 7 | GO:0032526 | Response to retinoic acid | 51 | 4 | 0.5927 | 0.0029 |
| 8 | GO:0006024 | Glycosaminoglycan biosynthetic process | 30 | 3 | 0.3486 | 0.0050 |
| 9 | GO:0006635 | Fatty acid beta-oxidation | 28 | 3 | 0.3254 | 0.0041 |
| 10 | GO:0010811 | Positive regulation of cell-substrate adhesion | 29 | 3 | 0.3370 | 0.0045 |
| 11 | GO:0030513 | Positive regulation of BMP signaling pathway | 31 | 3 | 0.3602 | 0.0055 |
| 13 | GO:0048704 | Embryonic skeletal system morphogenesis | 38 | 3 | 0.4416 | 0.0097 |
| 14 | GO:0090090 | Negative regulation of canonical Wnt receptor signaling pathway | 71 | 4 | 0.8251 | 0.0093 |
| 15 | GO:0030326 | Embryonic limb morphogenesis | 39 | 3 | 0.4532 | 0.0104 |
| 16 | GO:0009411 | Response to UV | 41 | 3 | 0.4765 | 0.0119 |
| (2)—2 clusters | ||||||
| 17 | GO:0004725 | Protein tyrosine phosphatase activity | 84 | 5 | 1.0065 | 0.0033 |
| 18 | GO:0015293 | Symporter activity | 43 | 4 | 0.5152 | 0.0017 |
| (3)—1 clusterr | ||||||
| 19 | GO:0005883 | Neurofilament | 9 | 3 | 0.1026 | 0.0001 |
Differentially regulated genes in EBS-DM KEB7 versus wild-type NEB1 cells were assigned GO terms and classified into clusters, which were further classified as biological processes (1), molecular functions (2) and cellular components (3). Statistical significance of each term was calculated by a one-sided hypergeometric test; a cluster with an adjusted p-value <0.05 was considered significant. Per cluster, a minimum of 3 genes (up- or down-regulated) is significant, equating to nearly 10 % of all annotated genes per enriched term
Fig. 2Western blot analysis for confirmation of differential expression at the protein level of 3 selected candidates—KRT19, WNT5a and SOX2. GAPDH occurred as normalization protein